Clene Inc. (CLNN) News

Clene Inc. (CLNN): $2.52

-0.13 (-4.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLNN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter CLNN News Items

CLNN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CLNN News Highlights

  • For CLNN, its 30 day story count is now at 7.
  • Over the past 29 days, the trend for CLNN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • MS, CNM and TA are the most mentioned tickers in articles about CLNN.

Latest CLNN News From Around the Web

Below are the latest news stories about Clene Inc that investors may wish to consider to help them evaluate CLNN as an investment opportunity.

Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022

VISIONARY-MS Phase 2 blinded interim data suggest clinically relevant improvements in the modified MS Functional Composite for the study population through 48 weeks of treatment REPAIR-MS Phase 2 clinical trial demonstrated improved brain energetic metabolism following CNM-Au8® treatment SALT LAKE CITY, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical compan

Yahoo | February 24, 2022

Clene Nanomedicine to Present Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2022

SALT LAKE CITY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will present updated blinded data from its VISIONARY-MS study and results from its REPAIR-MS trial in the stable relapsing MS population at the Americas Committee for Treatment and Research in

Yahoo | February 18, 2022

Clene Nanomedicine Provides Clinical Program Update

Healey ALS Platform Trial fully enrolled; top-line data expected 2H 2022Significant survival benefit from RESCUE-ALS open label extension (OLE) Phase 2 trial to be presented at upcoming Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Nashville, TN March 13-16, 2022VISIONARY-MS to conclude early due to COVID pandemic-related challenges. Unblinded data expected 2H 2022; insights to inform new Phase 2/3 MS trial. REPAIR-MS Phase 2 Trial initiates second cohort to confirm ta

Yahoo | February 14, 2022

Maxim Group Thinks Clene’s Stock is Going to Recover

Maxim Group analyst Naz Rahman maintained a Buy rating on Clene (CLNN – Research Report) on February 2 and set a price target of $9.00. The company's shares closed last Friday at $2.84, close to its 52-week low of $2.36. According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -38.8% and a 4.3% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Vertex Pharmaceuticals, and Galmed Pharmaceuticals. The the analyst consensus on Clene is currently a Moderate Buy rating.

Howard Kim on TipRanks | February 6, 2022

Hedge Fund and Insider Trading News: Ken Griffin, Kyle Bass, Steve Cohen, ARK36, Borea Asset Management, Whale Rock Capital Management, Elliott Management, Clene Inc. (CLNN), and More

Steve Cohen’s Point72 Asset Management lost money in January, making it an outlier as several multistrategy hedge funds posted gains during a volatile start of the year for stocks.

Insider Monkey | February 3, 2022

Clene Announces New Chief Financial Officer Morgan Brown

SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022. “Morgan joins the executive team at a pivotal time in Clene’s growth,” stated Clene’s President and CEO, Rob Ethering

Yahoo | February 1, 2022

Breakeven On The Horizon For Clene Inc. (NASDAQ:CLNN)

We feel now is a pretty good time to analyse Clene Inc.'s ( NASDAQ:CLNN ) business as it appears the company may be on...

Yahoo | January 26, 2022

Clene Nanomedicine’s Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial

Topline data is expected in 1H 2022Trial is evaluating acutely symptomatic, non-hospitalized COVID-19 patients in Brazil CNM-ZnAg is a proprietary zinc-silver ionic solution that has demonstrated both antiviral and antibacterial activity. SALT LAKE CITY, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced it has enrolled more than 50% o

Yahoo | January 18, 2022

Zacks: Brokerages Anticipate Clene Inc. (NASDAQ:CLNN) Will Announce Earnings of -$0.18 Per Share

Equities analysts expect that Clene Inc. (NASDAQ:CLNN) will post earnings per share (EPS) of ($0.18) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Clenes earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.17). The company is scheduled to issue [] The post Zacks: Brokerages Anticipate Clene Inc. (NASDAQ:CLNN) Will Announce Earnings of -$0.18 Per Share appeared first on ETF Daily News .

ETF Daily News | December 18, 2021

Clene Nanomedicine’s Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validated Across Europe

Powerful combination of key patents comes as the Company looks ahead to topline results from a Phase 3 registration study in ALS in second half of 2022 SALT LAKE CITY, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, announced it has validated key patents granted by the European P

Yahoo | December 15, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3353 seconds.